MyMD Pharmaceuticals Inc. (NASDAQ:MYMD) shares traded 1.38% higher at $2.20 on Wall Street last session.
MYMD stock price is now 24.37% away from the 50-day moving average and -15.78% away from the 200-day moving average. The market capitalization of the company currently stands at $81.22M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
.
In other news, Rivard Paul, EVP of Operations, GC bought 10,000 shares of the company’s stock on Dec 08. The stock was bought for $15,300 at an average price of $1.53. Upon completion of the transaction, the EVP of Operations, GC now directly owns 225,000 shares in the company, valued at $0.49 million. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MYMD stock. A new stake in MyMD Pharmaceuticals Inc. shares was purchased by INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC during the first quarter worth $147,000. FIDELIS CAPITAL PARTNERS, LLC invested $85,000 in shares of MYMD during the first quarter. In the first quarter, TWO SIGMA INVESTMENTS, LP acquired a new stake in MyMD Pharmaceuticals Inc. valued at approximately $66,000. UBS GROUP AG acquired a new stake in MYMD for approximately $16,000. In total, there are 51 active investors with 10.70% ownership of the company’s stock.
MyMD Pharmaceuticals Inc. (NASDAQ: MYMD) opened at $2.2500 on Tuesday. During the past 12 months, MyMD Pharmaceuticals Inc. has had a low of $0.90 and a high of $6.15. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.50, and a quick ratio of 4.50. The fifty day moving average price for MYMD is $1.7689 and a two-hundred day moving average price translates $2.6123 for the stock.
The latest earnings results from MyMD Pharmaceuticals Inc. (NASDAQ: MYMD) was released for Sep, 2022.
MyMD Pharmaceuticals Inc.(MYMD) Company Profile
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
